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Clinical effectiveness of pre-exposure prophylaxis 
(PrEP) for preventing HIV acquisition in men who have 
sex with men (MSM) at high HIV risk is established. 
A static decision analytical model was constructed 
to inform policy prioritisation in England around 
cost-effectiveness and budgetary impact of a PrEP 
programme covering 5,000 MSM during an initial high-
risk period. National genitourinary medicine clinic 
surveillance data informed key HIV risk assumptions. 
Pragmatic large-scale implementation scenarios were 
explored. At 86% effectiveness, PrEP given to 5,000 
MSM at 3.3 per 100 person-years annual HIV incidence, 
assuming risk compensation (20% HIV incidence 
increase), averted 118 HIV infections over remaining 
lifetimes and was cost saving. Lower effectiveness 
(64%) gave an incremental cost-effectiveness ratio 
of + GBP 23,500 (EUR 32,000) per quality-adjusted 
life year (QALY) gained. Investment of GBP 26.9 mil-
lion (EUR 36.6 million) in year-1 breaks even anywhere 
from year-23 (86% effectiveness) to year-33 (64% 
effectiveness). PrEP cost-effectiveness was highly 
sensitive to year-1 HIV incidence, PrEP adherence/
effectiveness, and antiretroviral drug costs. There is 
much uncertainty around HIV incidence in those given 
PrEP and adherence/effectiveness, especially under 
programme scale-up. Substantially reduced PrEP drug 
costs are needed to give the necessary assurance of 
cost-effectiveness, and for an affordable public health 
programme of sufficient size.
Introduction 
In the United Kingdom (UK) new prevention initiatives 
are needed to reduce the estimated 2,800 incident HIV 
infections occurring annually in men who have sex with 
men (MSM) [1]. The UK PROUD study demonstrated that 
HIV pre-exposure prophylaxis (PrEP) with daily oral 
antiretroviral (ARV) drug combination tenofovir diso-
proxil and emtricitabine in addition to standard-of-care 
risk reduction for MSM at high HIV risk, reduced HIV 
incidence over the participant follow-up period by 86% 
(90% confidence interval (CI): 64–96%) [2]. The PROUD 
data on PrEP effectiveness, supported by the placebo-
controlled efficacy data from iPrEX and IPERGAY, 
showed that PrEP offers a major opportunity to reduce 
HIV incidence in MSM [3,4]. A PrEP policy was proposed 
by National Health Service (NHS) England for high HIV 
risk attendees of the 215 genitourinary medicine (GUM) 
clinics in England that provide free, confidential, open-
access sexual health services [5].
In England, new clinical commissioning policies are pri-
oritised on their effectiveness and value for money [6]. 
Cost-effectiveness evidence is reviewed, with incre-
mental value for money of competing services scored 
and compared on the basis of their incremental costs 
and incremental benefits. In other areas of publically 
funded public health prevention programmes (e.g. 
immunisation), one decision criterion used is a high 
certainty that the incremental cost-effectiveness ratio 
(ICER) falls below a recommended threshold, currently 
GBP 20,000 (EUR 27,210) per quality-adjusted life year 
(QALY) gained [7,8]. In addition, the affordability of any 
new service must be ensured based on practical eligi-
bility criteria that are developed to guarantee the ser-
vice reaches those with greatest need [6].
A static decision analytical model was used to explore 
the economic implications of a first phase scale-up of 
a PrEP programme for MSM GUM clinic attendees at 
high HIV risk, beginning in 2016. The method is valid 
for a modest scale initial PrEP programme with limited 
indirect (herd) effect [9], and was chosen for the rela-
tively limited assumptions required, its transparency 
and ease of interpretation for decision makers, and 
because of the increasing uncertainties when estimat-
ing costs and effects after 5 to 10 years. Moreover, the 
technique was suitable because the impact on popu-
lation disease dynamics is likely to be limited in the 
early years of a PrEP policy given the small numbers 
protected relative to the total at risk [9].
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Methods
The perspective of a healthcare provider was taken. A 
5,000 person-years PrEP coverage level was judged to 
be reasonable for this initial scale-up period, based 
on the range suggested by a multidisciplinary, multi-
stakeholder group of clinicians, patients, commission-
ers (budget holders) and public health practitioners 
[5]. The 4,500–6,500 range was generated after con-
sidering the evidence around likely programme roll-out 
scenarios, the GUM clinic activity dataset (GUMCAD) 
estimated need, patient-level uptake as informed by 
community surveys about willingness to take PrEP, 
and considered potential organisational challenges of 
delivery across many GUM clinics as well as evidence 
of PrEP scale-up in other countries [10].
The lifetime HIV risk of 5,000 MSM who began an initial 
high HIV risk period of one year on PrEP was compared 
with the lifetime risk of the same group in the absence 
of PrEP (Figure 1). This required age distribution of MSM 
at high behavioural risk and estimates of HIV acquisi-
tion during the high-risk period of PrEP eligibility, as 
well as estimates of lifetime HIV acquisition, to account 
for the residual HIV risk after the high-risk period had 
passed. PrEP provision to a single high-risk year was 
modelled at the cohort-level. At the individual-level, 
should high risk continue beyond the first year, then 
that individual will form part of a new high-risk cohort 
in the second year. The ICER for PrEP remains the same 
for the second cohort as for the previous year’s high-
risk cohort.
Data were extracted from GUMCAD [11], a comprehen-
sive, pseudo-anonymised digital download of patient-
level data on all sexually transmitted infection (STI) 
services and diagnoses provided in GUM clinics in 
England. Each pseudo-anonymised record contains 
a clinic identifier as well as a local patient number, 
so data from the same individual attending the same 
clinic can be linked longitudinally. Estimates of lifetime 
HIV risk were adjusted to the age-distribution of MSM 
GUM clinic attendees, using averages for years 2013–
14 (see supplementary material [12]).
In the principal scenarios, MSM receiving PrEP were 
assumed to be prescribed daily tenofovir disoproxil and 
emtricitabine combined tablet, in accordance with the 
European Medicines Agency licensed prevention indi-
cation [13]. Event-based dosing (i.e. PrEP given before 
and after sexual exposure) for an average of four tab-
lets used per 7-day period, was explored in sensitivity 
analyses [4].
Figure 1
Decision analytical model structure comparing no-PrEP 
with PrEP in 5,000 men who have sex with men at high 
HIV riska, England, 2016
Subsequent lifetime 
HIV negative (4,152) 
Subsequent lifetime 
HIV positive  (683) 
Subsequent lifetime HIV negative  
(4,152) 
Year 1 HIV negative  
(4,835) 
Year 1 HIV positive 
(165) 
No PrEP in Year 1 
HIV-PrEP in Year 1 
Year 1 HIV positive 
(86% eﬀectiveness: 28) 
(64% eﬀectiveness: 71)
Year 1 HIV negative  
(86% eﬀectiveness: 137 protected) 
(64% eﬀectiveness: 94 protected) 
Subsequent lifetime HIV positive 
(86% eﬀectiveness: 19) 
(64% eﬀectiveness: 13) 
Subsequent lifetime HIV negative  
(86% eﬀectiveness: 118) 
(64% eﬀectiveness: 81) 
Year 1 HIV negative  
(4,835) 
Subsequent lifetime HIV positive  
(683) 
(5,000 HIV negative MSM)
(5,000 HIV negative MSM)
MSM: men who have sex with men; PrEP: pre-exposure 
prophylaxis.
Red and green colours are used to indicate the estimated numbers 
of HIV-positive or negative MSM respectively, after a defined 
period (i.e. after the first year of PrEP (year-1) or, for the control 
group, after year-1 without PrEP, and for the remaining lifetime 
in both groups).
a HIV incidence in Year-1 is 3.3 per 100 person-years and cumulative 
lifetime incidence without PrEP is 16.96%.
Figure 2
Impact of year-1 PrEPa on HIV incidence over 10 years for 
5,000 MSM at initial high HIV risk, England, 2016–2025
            
 
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0
20
40
60
80
100
120
140
160
180
1 2 3 4 5 6 7 8 9 10
Ne
w
 H
IV
 In
fe
ct
io
ns
W
eighted HIV Incidence 
(per 100 PYs)
Years
No HIV-PrEP in Year-1
HIV-PrEP in Year-1, 86% eﬀective + risk compensation
HIV-PrEP in Year-1, 64% eﬀective + risk compensation
Weighted average annual HIV incidence
HIV risk: 3.3 per 100 PYs
HIV risk:
1.35 per 100 PYs
HIV risk: <1 per 100 PYs
PrEP: pre-exposure prophylaxis; PYs: person-years.
The bars on this chart represent the number of new HIV infections 
by year: (i) In the absence of PrEP (blue bars); (ii) If PrEP is given 
in year-1 and assuming 86% effectiveness + risk compensation 
(turquoise bars); (iii) and if PrEP is given in year-1 and assuming 
64% effectiveness + risk compensation (green bars).
Up to age 75 years, there were 848 HIV infections without PrEP, 
and 730 with PrEP at 86% effectiveness and 767 with PrEP at 
64% effectiveness. Slightly more later-HIV infections occur in 
those given PrEP during year-1 as the MSM protected by PrEP 
become susceptible on stopping PrEP, albeit at a much lower 
risk level.
a PrEP effectiveness at either 86% or 64%, both with risk 
compensation adjustment (see text).
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Figure 3
Multivariate sensitivity of incremental cost-effectiveness ratio (ICER) for different levels of pre-exposure prophylaxis (PrEP) 
effectiveness, England, 2014/15 cost values
44%  64%  86%  96%  
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(EUR 0 < ICER < EUR 27,210)
GBP 20,000 < ICER < GBP 30,000
(EUR 27,210 < ICER < EUR 40,815)
ICER > GBP 30,000
(ICER > EUR 40,815)
1. Year-1 HIV incidence
(no risk compensation)
2. Risk compensation 
in those given PrEP, 
as percentage increase 
in HIV incidence 
(Year-1 HIV incidence: 
3.3 per 100 person-years)
3. Percentage reduction in 
ARV treatment cost from 
2019 
(Year-1 HIV incidence: 
3.3 per 100 person-years; 
risk compensation in 
those given PrEP of 
20% HIV incidence 
increase)
4. Percentage reduction 
in PrEP BNF annual 
drug price 
(Year-1 HIV incidence: 
3.3 per 100 person-years; 
risk compensation in those 
given PrEP – 20% HIV 
incidence increase; 
30% reduction in 
ARV treatment cost 
after 2019)
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21% GBP 3,403f
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(EUR 3,367)
90% GBP 431h
(EUR 586)
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(EUR 45,789)
-GBP 38,072
(-EUR 51,797)
-GBP 46,355
(-EUR 63,066)
-GBP 49,947
(-EUR 67,953)
-GBP 50,921
(-EUR 69,278)
-GBP 4,934
(-EUR 6,713)
-GBP 21,669
(-EUR 29,481)
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(EUR 90,147)
-GBP 14,974
(-EUR 20,372)
-GBP 26,208
(-EUR 35,656)
GBP 13,893
(EUR 18,901)
-GBP 8,816
(-EUR 11,994)
GBP 98,864
(EUR 134,504)
GBP 32,721
(EUR 44,517)
GBP 4,038
(EUR 5,494)
-GBP 3,741
(-EUR 5,090)
GBP 114,289
(EUR 155,490)
GBP 48,146
(EUR 65,503)
GBP 19,463
(EUR 26,479)
GBP 11,684
(EUR 15,896)
GBP 105,034
(EUR 142,899)
GBP 38,891
(EUR 52,911)
GBP 10,208
(EUR 13,888)
GBP 2,429
(EUR 3,305)
GBP 32,721
(EUR 44,517)
GBP 4,038
(EUR 5,494)
-GBP 3,741
(-EUR 5,090)
GBP 23,465
(EUR 31,924)
-GBP 5,218
(-EUR 7,099)
-GBP 12,997
(-EUR 17,682)
GBP 29,582
(EUR 40,246)
-GBP 4,161
(-EUR 5,661)
-GBP 12,769
(-EUR 17,372)
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(EUR 31,924)
-GBP 5,218
(-EUR 7,099)
-GBP 12,997
(-EUR 17,682)
GBP 18,078
(EUR 24,595)
-GBP 6,239
(-EUR 8,488)
-GBP 13,222
(-EUR 17,989)
GBP 13,296
(EUR 18,089)
-GBP 7,227
(-EUR 9,832)
-GBP 13,446
(-EUR 18,293)
GBP 64,630
(EUR 87,929)
GBP 30,980
(EUR 42,148)
GBP 20,783
(EUR 28,275)
3.3 per 100 
person-years
GBP 7,786
(EUR 10,593)
GBP 49,762
(EUR 67,701)
GBP 13,296
(EUR 18,089)
-GBP 7,227
(EUR 9,832)
-GBP 13,446
(EUR 18,293)
-GBP 15,572
(-EUR 21,186)
-GBP 28,717
(-EUR 39,069)
-GBP 32,701
(-EUR 44,490)
-GBP 23,010
(-EUR 31,305)
-GBP 36,764
(-EUR 50,017)
-GBP 44,504
(-EUR 60,548)
-GBP 46,850
(-EUR 63,739)
PrEP eﬀectivenessb
Parameter combinationsa
BNF: British National Formulary; GUM: genitourinary medicine; GUMCAD: GUM clinic activity dataset; MSM: men who have sex with men; STI: sexually transmitted infection; UK: United Kingdom.
a First parameter combination (i.e. Year-1 HIV incidence of 3.3 per 100 person-years) assumed within second combination, first and second within third, etc.
b 44% was the efficacy level reported in the iPrEx trial; 86% was the UK PROUD trial observed clinical effectiveness level, while 64% and 96% were the lower- and upper-bound 90% confidence intervals reported in 
this latter trial [2,3].
c Reported HIV incidence in the deferred part (no PrEP, n = 267 MSM) of the PROUD trial [2].
d Estimated HIV incidence in HIV-negative MSM with documented rectal bacterial STI diagnosis in 2012, GUMCAD analysis.
e Estimated HIV incidence in all HIV-negative MSM GUM attendees in 2012, GUMCAD analysis.
f 21% reduction in PrEP drug price due to 50% event-based dosing i.e. prorated 5.5 tablets per 7-day. This assumed that if an MSM was prescribed event-based dosing, then only four tablets would be dispensed for 
every 7-day i.e. 4/7 of the drug cost. Event-based dosing frequency based on the findings reported in the IPERGAY trial [4]. Service provision through GUM clinics remained the same, as frequency of monitoring 
remained the same.
g 43% reduction in PrEP drug price due to 100% event-based dosing (four tablets per 7-day).
h 90% reduction in PrEP drug price due to fall in current tenofovir disoproxil/emtricitabine price following patent expiry of the PrEP drug used. This is an arbitrary assumption. The future price is dependent on market 
competition. The exact timing of when this will happen, however, is uncertain. The patents for tenofovir disoproxil and emtricitabine expired in 2016 and July 2017, respectively. However, Truvada as a combination 
tablet containing both tenofovir disoproxil/emtricitabine has a supplementary protection certificate (SPC) providing market exclusivity protection until February 2020, although this SPC is being challenged [39].
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Individuals given PrEP will be managed via GUM clin-
ics; for a one year programme, each individual will have 
five visits to the clinic, at month 0, 1, 3, 6, and 9. The 
first visit includes assessment of clinical need for PrEP, 
confirmation of HIV and STI status, and measurement 
of renal function. Subsequent visits are for monitoring 
of drug adherence, tolerability, and safety, together 
with quarterly checking of HIV and STI status [2]. The 
additional elements of GUM clinic care directly attrib-
utable to PrEP were micro-costed (see supplementary 
material [12]).
Estimating HIV incidence
GUMCAD data on HIV-negative clinic attending MSM 
for 2009 to 2013 were extracted. Diagnosis or not of 
any bacterial STI in the previous year was used to indi-
cate recent condomless anal intercourse and to stratify 
the future risk of being diagnosed with HIV. Those with 
a bacterial STI in the previous year were labelled ‘high-
risk’ and eligible for PrEP, and those without as having 
‘medium-risk’ for HIV acquisition [14]. To estimate cur-
rent HIV incidence in these strata, records were used 
of MSM with at least one additional documented HIV 
test between 43 to 365 days after the first HIV test 
Figure 4
Univariate sensitivity of pre-exposure prophylaxis (PrEP) incremental cost-effectiveness ratio (ICER) around base casea for 
plausible rangesb of key parameters, 2014/15 cost values
5,000 high-risk MSM person-years; 3.3 per 100 person-years Year 1 incidence; 64% eﬀectiveness + 20% HIV incidence increase when given HIV-PrEP as risk compensation
input input input ICER (output) ICER (output) ICER (output)
lower base case upper lower base case upper
Disutility in undiagnosed HIV 0.11-                      -                        21,632.94 23,465.43 1,832                                
Disutility in diagnosed HIV -                        2,499.00              23,465.43 21,537.24 1,928                                
Annual care cost of undiagnosed HIV -0.13 -0.11 -0.10 20,609.24 23,465.43 25,212.50 4,603                                
Risk compensation (see text) 0% 20% 30% 13,295.96 23,465.43 29,582.40 16,286                              
Reduction in ARV  treatment cost from 2019 0% 80% 23,465.43 48,146.14 24,681                              
Discount rate for future costs and QALYs 1.50% 3.50% -3,684.12 23,465.43 27,150                              
Event-based (4/7) Dosing 0% 100% 23,465.43 -13,152.83 36,618                              
Reduction in HIV-PrEP BNF Annual Drug Price 90% 0% -55,609.87 23,465.43 79,075                              
Year-1 HIV incidence (per 100 person-years) 0.44                      0.64                      0.96                      89,608.29 23,465.43 -12,996.52 102,605                            
PrEP eﬀectiveness 2.00                      3.30                      9.00                      81,304.04 23,465.43 -32,928.30 114,232                            
 GBP -80K  GBP -60K  GBP -40K  GBP -20K  GBP 0 GBP 20K GBP 40K GBP 60K GBP 80K GBP 100K
EUR -109K  EUR -82K  EUR -54K  EUR -27K  EUR 0 EUR 27K EUR 54K EUR 82K GBP 109K EUR 136K
Disutility in undiagnosed HIV
Disutility in diagnosed HIV
Annual care cost of undiagnosed HIV
Risk compensation (see text)
Reduction in ARV  treatment cost from 2019
Discount rate for future costs and QALYs
Event-based (4/7) Dosing
Reduction in HIV-PrEP BNF annual drug price
Year-1 HIV incidence (per 100 person-years)
PrEP eﬀectiveness 44%
2
0%
0%
3.50%
80%
30%
0.10
GBP 0
(EUR 0)
Base 
9
96 %
90%
100%
1.50%
0%
0%
0.13
0.11 0
GBP 2,499
EUR (3,400)
ARV: antiretroviral; BNF: British National Formulary; QALY: quality-adjusted life year.
a Base case ICER + GBP 23,500 (EUR 31,900) per QALY gained, set at 64% PrEP effectiveness and a 20% increase in HIV incidence in those given 
PrEP due to risk compensation (see text).
b Extremes of parameter ranges shown at either end of horizontal bars.
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Table 1
Economic parameter estimates used in the two principal scenarios (providing PrEP or not), and value or range explored in 
sensitivity analyses, England, 2014/15 cost values
Parameter Value
Sensitivity analyses range 
(min. to max. value of 
scenarios considered)
Explanatory notes and data source
Discount rate (cost) 3.5%   1.5% – 3.5%   [7]
Discount rate (QALYs) 3.5%   1.5% – 3.5%   [7]
Costs
Annual cost of PrEP drug
GBP 4,331 
 
(EUR 5,892)
  GBP 433 – GBP 4,331 
 
  (EUR 589 – EUR 5,892) 
 
  Discount range:  
 
  20% to 90%
  [32] (last accessed 5 August 2016); price 
excludes VAT and was directly applied to the 
cost-effectiveness analysis
Annual cost of PrEP-related GUM tariffs
GBP 176 
 
(EUR 239)
  ND   [2,33], see also supplementary material [12]
PEPSE drug costa (averted in those taking PrEP)
GBP 772a 
 
(EUR 1,050)  
 
per PEPSE 
course
  NA
  [32] (BNF last accessed 5 August 2016); price 
excludes VAT and was directly applied to the 
cost-effectiveness analysis
PEPSE GUM clinic costs (averted in those taking 
PrEP)
GBP 250 
 
(EUR 340) 
 
per PEPSE 
course
  NA   [33] (adapted to the current study)
Annual cost of an undiagnosed HIV infection
GBP 0  
 
(EUR 0)
  GBP 0 – GBP 2,499 
 
  (EUR 0 – EUR 3,400)
  Assumption; GBP 2,499 based on HIV care 
costs for individuals diagnosed at CD4+ > 200 
cells per mm3 not on ARV treatmentb [17,21]
Annual cost of ARV treatment per 
HIV-positive individual
GBP 4,741  
 
(EUR 6,450)
  Price reductions from 
2019:  
 
  range 0% to 80%
  [20]c
Annual care cost of HIV + CD4 > 200 cells per 
mm3
GBP 4,734  
 
(EUR 6,441)
  ND   [17,21]
Annual care cost of HIV + CD4 < 200 cells per mm3
GBP 7,479  
 
(EUR 10,175)
  ND   [17,21]
Time to CD4+ recovery from < 200 cells per mm3 3 months   NA   Based on analysis of HIV data [18]
QALY values
Disutility between HIV infection and diagnosis 0   0 – 0.11   Assumption [34]
Disutility associated with HIV infection – per 
annum 0.11   0.10 – 0.13   [34]
Utility values in UK men aged over 75 yearsd 0.75   NA   [35]
ARV: antiretroviral; BNF: British National Formulary; GUM: genitourinary medicine; max: maximum; min: minimum; NA: not applicable; ND: not 
done; NHS: National Health Service; NICE: The National Institute for Health and Care Excellence; PEPSE: post-exposure prophylaxis; PrEP: 
pre-exposure prophylaxis; QALY: quality-adjusted life year; VAT: value added tax; UK: United Kingdom.
a This price represents the highest possible cost of current PEPSE drug recommended for use by NHS England (tenofovir disoproxil/
emtricitabine/raltegravir) based on BNF list price, excluding VAT for the cost-effectiveness analysis in accordance with NICE Methods Guide.
b Cost excludes specific HIV-related costs such as CD4+ and viral load measurements, and resistance testing (personal communication, V 
Cambiano, December 2015).
c Principal scenario used NHS England reported spend on ARV treatment. In sensitivity analyses, although actual timing of availability of 
generic ARVs for treatment is unknown, sensitivity analyses explored potential availability from 2019. This was based on the estimated 
patent expiration of individual compounds of the combination ARV treatment tenofovir disoproxil/emtricitabine/efavirenz (proprietary 
name: Atripla) by 2018 [36]. Combination tenofovir disoproxil/emtricitabine/efavirenz is one of the British HIV Association preferred choice 
of ARV treatment to begin with in therapy-naïve patients [37].
d We assumed that an HIV-positive individual has a life-expectancy of 75 years [38]. Given that the life-expectancy at birth for males in 
England (2010 to 2012 Office for National Statistics estimates) was 79 years, this meant that an HIV-positive individual who dies at age 75 
years would have lost four years of quality of life [16]. We combined this last four years with the utility values among UK men aged above 75 
years (0.75 per year), which was obtained from the EQ-5D utility values for UK male population, to obtain the QALY losses during these final 
four years of life lost consequent to earlier deaths related to HIV [35].
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documented in 2012, the most recent year with suffi-
cient data (followed-up to end 2013) for analysis [14]. 
HIV incidence estimation methodology follows that 
used in Desai et al. [14].
MSM who did not attend a GUM clinic were assumed to 
be at ‘low-risk’ [14] (see also supplementary material 
[12]). To estimate HIV incidence in this stratum, total 
MSM numbers were calculated by combining the male 
proportion reporting same-sex partnerships in a 2010–
12 national survey with 2012 male population estimates 
[15,16]. Estimated MSM living with HIV (diagnosed and 
undiagnosed) and GUM attending HIV-negative MSM 
were subtracted to get the denominator of those at 
low-risk [1]. Estimated HIV infections that occur in high- 
and medium-risk MSM were subtracted from the back-
calculation estimate of all 2012 HIV infections in MSM 
to give the numerator for those at low-risk.
MSM eligible for PrEP begin at high-risk and move to 
medium- or low-risk at a changing probability. Lifetime 
HIV incidence combined movement between risk 
strata with estimated stratum-specific HIV incidence. 
Follow-up of high-risk MSM clinic attendees informed 
the proportions that stayed high-risk with bacterial STI 
diagnoses each year, those that became medium-risk 
who attended a clinic annually without bacterial STI 
diagnosis, and those without clinic attendance who 
became low-risk. Allowance was made for any transi-
tion from low- or medium-risk back to medium- or high-
risk. If in 2013, x% of MSM who began as high-risk in 
2009 remained high-risk, y% had become medium-
risk, and z% low-risk, and HIV incidence was  Η,  Μ, 
and  Λ  for high, medium, and low-risk respectively, 
then the weighted average HIV incidence in 2013 was 
(x%*Η) + (y%*Μ) + (z%*Λ). Similarly calculated weighted 
HIV incidence averages were used for years 2010, 2011 
and 2012. By assuming the same rate of change in risk 
from 2009 through 2013 and the same HIV incidence 
by risk stratum, future HIV incidence in 2017 through 
2020 was estimated for MSM who began as high-risk 
in 2016 (PrEP programme year-1). After year-5 in 2020, 
future annual HIV incidence was interpolated using a 
constant rate of reduction until it reached Λ, and sub-
sequently kept at  Λ  until age 75 years, after which 
risk of HIV acquisition was assumed to be zero. This 
approach created a declining HIV incidence over time. 
A slightly higher number remained susceptible in the 
PrEP group due to their PrEP protection during the first 
year. Therefore, over the subsequent lifetime to age 75 
years, the absolute number of HIV infections each year 
was slightly greater in the PrEP group compared with 
the non-PrEP group (Figure 2).
Economic evaluation
A national guide for technology appraisals was fol-
lowed [7]. PrEP users were assumed not to require HIV 
post-exposure prophylaxis following sexual exposure 
(PEPSE). Lifetime HIV infection care cost (excluding 
ARV costs) were stratified by CD4+ status at diagno-
sis [7,17]. HIV surveillance data were used to estimate 
average time to diagnosis once infected, CD4+ count at 
diagnosis, and rate of CD4+ recovery upon ARV com-
mencement [18] (see also supplementary material [12]). 
Prompt initiation of ARV treatment following diagnosis 
was assumed [19].
Table 2
Population size and HIV incidence in men having sex with men (MSM), England, 2012
HIV-negative MSM by risk stratum MSM numbersa Annual HIV incidence, per 100 person-years (95% CI)
Annual HIV 
infectionsa
a. HIV incidence in GUM clinic attendees (directly estimatedb)
High-risk – GUM clinic attendees with bacterial STI in previous year and/
or at first attendance of year 17,400 3.3 (2.8–4.9)
c 570d
Medium-risk – GUM clinic attendees with no recorded bacterial STI in 
previous year or at first attendance of year 68,100 1.5 (1.3–1.8)
c 1,020d
b. Overall HIV incidence, England
PHE back-calculatione 2,790
c. HIV incidence in non-GUM clinic attendees (indirectly estimatedf)
Low-risk – HIV-negative non-GUM clinic attendees 395,000 0.3 1,200
CI: confidence interval; GUM: genitourinary medicine; ONS: Office for National Statistics; MPES: multi-parameter evidence synthesis; Natsal: 
National Survey on Sexual Attitudes and Lifestyles; PHE: Public Health England; STI: sexually transmitted infection.
a Numbers rounded to three significant figures or nearest 10.
b Estimated using 2013 Genitourinary Medicine Clinical Activity Dataset – GUMCAD [11].
c As observed in re-attending sub-group.
d Applying observed incidence to whole group and rounded to three significant figures or nearest 10.
e Year 2012 estimated numbers, using methodology as described in Birrell et al., 2013 [30].
f Estimated 1,200 annual infections calculated by deducting number of infections among GUM clinic attendees (high-risk and medium-risk; 
1,595) from overall annual HIV incidence (2,790) [30]. Low-risk population size of 395,000 (i.e. non-GUM attending MSM) estimated using 
a combination of MPES (England and Wales, aged 15–44 years), ONS (England and Wales population estimates for mid-2012), and Natsal-3 
(proportion of MSM by age group), to obtain an estimate of the non-GUM attending MSM population in England for ages 15–74 years 
[1,15,16]. HIV incidence in this low-risk group (1,200 annual infections per 395,000 population) rounded to 0.3 per 100 person-years.
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Drug treatment costs used average 2013–15 NHS 
England ARV cost [20]. Future costs and QALYs were 
discounted annually by 3.5% and adjusted to 2014/15 
GBP values (EUR values presented in parentheses, 
using year end 31 December 2015 historical exchange 
rates of GBP 1 equals EUR 1.3605) [7,21]. Economic 
parameters are presented in Table 1.
Model outputs included number of new HIV infections 
and the ICER, as cost per QALY gained, of PrEP com-
pared with no PrEP. Budget impact analyses were pre-
sented in present 2014/15 values and included value 
added tax (VAT: + 20%) on PrEP drug costs [7]. PrEP 
service investment time to break-even was calculated 
as the years to when the cumulative savings from HIV 
infections averted in year-1 began to exceed PrEP costs 
in year-1.
Risk compensation
Published evidence suggests increased frequency 
of condomless anal sex subsequent to PrEP use and 
increased STI diagnoses [2,22]. Risk compensation 
would also lead to an increase in HIV exposure. With 
PrEP scale-up, adherence may reduce and thereby 
increase HIV transmission. To explore risk compensa-
tion, an arbitrary increase of HIV incidence by 20% in 
those given PrEP was assumed in the principal scenar-
ios. At 64% PrEP effectiveness, for example, annual HIV 
incidence is (100% – 64%) * Η = 36% * Η, where, Η = HIV 
incidence in high-risk MSM. If Η  is increased by 20% 
due to risk compensation, then annual HIV incidence 
becomes (100 – 64%)*(100% + 20%) *Η = 43.2% * Η.
Sensitivity analyses
Sensitivity analyses explored plausible ranges of key 
parameter values (Table 1). Univariate sensitivity analy-
ses were based on cautious choices considered more 
plausible with substantial scale-up. The scenario with 
64% PrEP effectiveness and risk compensation was the 
preferred benchmark and corresponding ICERs were 
plotted on a tornado diagram.
Multivariate sensitivity analyses were conducted to 
illustrate the margin of certainty around whether or 
not PrEP would remain cost-effective, at different PrEP 
effectiveness level (Figure 3). Due to the nature of the 
uncertainties, full probabilistic sensitivity analysis was 
not possible.
Results
An estimated 466,000 HIV-negative MSM aged between 
15 to 75 years-old live in England in 2012, 85,500 (23%) 
of whom attended GUM clinics during that year. A fifth 
of the 85,500 (17,400 MSM) had a documented bacte-
rial STI diagnosis i.e. proxy for high risk. Over time, 
GUMCAD data have shown an increase in the number 
of HIV-negative MSM GUM attendees, as well as the 
subset diagnosed with bacterial STI. Thus, the 5,000 
person-years PrEP covered 29% of the GUMCAD identi-
fied high-risk cohort (who may not represent all high-
risk MSM as not all attended GUM clinics [23]), 6% of all 
HIV-negative MSM GUM attendees, and just 1% of the 
estimated HIV-negative MSM population in England.
The HIV incidence observed in the high-risk PrEP-
eligible stratum was 3.3 per 100 person-years (95% 
CI: 2.8–4.9 per 100 person-years), and 1.5 per 100 
person-years (95% CI: 1.3–1.8 per 100 person-years) in 
the medium-risk stratum. In the low-risk MSM stratum 
the indirectly estimated HIV incidence was 0.3 per 100 
person-years (Table 2). The HIV incidence estimates 
showed that GUM attending MSM had higher HIV risk 
than non-GUM attending MSM.
Of the 11,742 MSM without diagnosed HIV and with 
a recent bacterial STI (proxy for high HIV risk), who 
attended clinic in 2009 (the first of a five year, 2009–
2013, longitudinal analysis), only 26% were categorised 
as high-risk in 2010. This decrease in the proportion of 
the initial 2009 attendees categorised as high-risk in 
subsequent years continued through 2011, 2012 and 
2013, to 10%, 7% and 5% (see supplementary material 
[12]). Consequently, there was a large reduction in the 
weighted average annual HIV incidence for year-2 to 
year-5 (Figure 2). Interpolating the declining risk behav-
iour in the cohort and subsequent HIV acquisition for-
ward, the annual HIV incidence reached the lower risk 
tier of 0.3 per 100 person-years annually by year-9, 
after which it was kept constant until age 75 years.
Combining the weighted average annual HIV incidence 
for MSM and the age distribution of MSM clinic attend-
ees in 2013 and 2014, the estimated lifetime HIV inci-
dence to age 75 years in an MSM clinic attendee who 
began year-1 at high-risk, was 16.96%.
Applying a 20% HIV incidence increase to those given 
PrEP in year-1, as a risk compensation adjustment, the 
estimated cumulative HIV incidence to age 75 years 
was reduced from 16.96% (no PrEP) to 15.4% at 64% 
PrEP effectiveness, while at 86% effectiveness, it fell 
to 14.6%.
After the year-1 high-risk period, HIV incidence reduced 
to 1.35 per 100 person-years and PrEP was no longer 
indicated. Moreover, a small fraction of those who were 
protected by PrEP during the first year became infected 
later in life. The contribution of PrEP, given only dur-
ing the year-1 high-risk period, to reducing lifetime HIV 
risk was modest, impacting on close to 20% of lifetime 
risk, because of the relatively short period that MSM 
remained at high risk (see supplementary material 
[12]).
Economic evaluation
Without PrEP in year-1, an estimated 848 HIV infections 
occurred, producing future discounted HIV care costs of 
GBP 84.3 million (EUR 115 million), and a loss of 1,830 
QALYs (discounted). Almost half of these infections 
occurred within the first 10 years (see supplementary 
material [12]).
22 www.eurosurveillance.org
Assuming daily PrEP at 86% effectiveness (with risk 
compensation), an estimated 730 lifetime HIV infec-
tions occurred. Year-1 PrEP cost (drug and GUM clinic) of 
GBP 22.5 million (EUR 30.7 million) prevented GBP 24.1 
million (EUR 32.9 million) HIV care costs (discounted) 
and GBP 256,000 (EUR 348,000) PEPSE-related costs, 
saved 361 QALYs (discounted), and over a lifetime was 
cost-saving (i.e. ICER is negative), compared with no 
PrEP. Delivering PrEP to 5,000 high-risk MSM resulted 
in 137 less year-1 HIV infections. However, 19 of these 
137 acquired HIV while at medium- or low-risk later 
in life, reducing the total infections prevented to 118. 
Nevertheless, these 19 infections were delayed with 
corresponding reductions in costs and QALY losses.
At 64% PrEP effectiveness (with risk compensation), 
the lifetime HIV infections were 767. Year-1 PrEP service 
cost of GBP 22.5 million (EUR 30.7 million) prevented 
GBP 16.5 million (EUR 22.4 million) HIV care costs 
(discounted) and GBP 256,000 (EUR 348,000) PEPSE-
related costs, and saved 247 QALYs (discounted). 
Under this scenario, the ICER increased to + GBP 23,500 
(EUR 31,900), just above the current cost-effectiveness 
threshold for England [7]. The reduced effectiveness 
gave 94 less year-1 HIV infections, although 13 of the 
94 acquired HIV in later years.
The ICER was very sensitive to assumptions about HIV 
incidence in the PrEP eligible group, PrEP effectiveness 
when scaled-up, PrEP drug costs, and future reduc-
tions in the cost of ARV treatment (Figure 4).
PrEP was much less cost-effective if HIV incidence was 
2 per 100 person-years (the estimated overall HIV inci-
dence in MSM GUM clinic attendees), or if PrEP effec-
tiveness dropped to 44%. Similarly, albeit to a lesser 
extent, reduced future treatment costs produced a less 
favourable ICER for PrEP. However, a more favourable 
ICER resulted through reducing PrEP drug costs, either 
through price reduction or reduced dosing frequency 
from daily to event-based.
If, under scale-up, PrEP stayed 86% effective with 20% 
HIV risk increase (risk compensation adjustment), then 
for most parameter combinations a PrEP policy stays 
cost-effective, unless the eligible group HIV incidence 
was 2 per 100 person-years or less (Figure 3). If, how-
ever, effectiveness was 64% with the same degree of 
risk compensation, then a PrEP service will only be 
cost-effective if year-1 incidence is over 3.3 per 100 
person-years and there is no change in future HIV treat-
ment costs (i.e. ignoring availability for treatment of 
generic ARVs by 2019, see notes for Table 1), or if PrEP 
drug cost is reduced.
Budgetary implications
In a single year, a PrEP service of 5,000 person years 
cost GBP 26.9 million (EUR 36.6 million), at current 
British National Formulary (BNF) list price (inclusive 
of 20% VAT). As HIV care costs accrued over time, it 
took many years before investment in the first year 
was recovered. At 86% PrEP effectiveness, it took 23 
years of cumulative savings from HIV care cost averted 
for the year-1 investment to break even and 33 years 
if PrEP was only 64% effective, both assuming risk 
compensation.
If there was a substantial reduction in PrEP drug price 
(e.g. by 90%), the budget to cover 5,000 person years 
became GBP 3.48 million (EUR 4.73 million). Break-
even of year-1 investment happened by the fifth year 
at 86% effectiveness or by the sixth year at 64% effec-
tiveness, again assuming risk compensation.
Time to break-even of the initial year of PrEP was 
extended should future HIV treatment costs reduce. At 
current BNF list price, a 30% reduction in future ARV 
treatment costs from 2019 onwards increased the time 
to break-even of the one-year investment in PrEP in 
2016 to 38 years, assuming 64% PrEP effectiveness 
with risk compensation.
Discussion 
Oral PrEP given to MSM at high HIV risk, assuming good 
adherence and correspondingly high clinical effective-
ness, was potentially cost-effective in England. The 
ICERs, however, were very sensitive to key parameters 
such as the risk of HIV for PrEP recipients and adher-
ence (effectiveness). When PrEP is scaled-up to ser-
vice provision level there is doubt that the values for 
these parameters observed in clinical trial settings will 
apply. Moreover, at the current BNF price the budgetary 
impact of a modest annual programme of 5,000 PrEP 
person years was considerable.
The cost-effectiveness of PrEP scale-up depends first 
on reaching those at high risk of HIV, who need to 
be identified, offered and to accept PrEP; if many at 
medium-risk take PrEP, HIV incidence in those taking 
PrEP will be overestimated. Second, PrEP adherence 
may be lower with scale-up than in smaller clinical tri-
als; results from ‘real-world’ effectiveness trials, which 
generally recruit committed early adopters who may 
be at exceptionally high-risk, may not be repeated in 
programmes for all at high-risk [24]. Third, there is 
uncertainty about whether or not condomless anal 
intercourse frequency will increase in those given PrEP 
(risk compensation), leading to more exposures and 
increased HIV in those with poor PrEP adherence as 
well as increased bacterial STIs and hepatitis C, thus 
blunting PrEP benefit; so far a possible HIV incidence 
increase mediated through diminished adherence 
during scale-up has not been observed, but there is 
emerging evidence suggesting risk compensation and 
bacterial STI increase in those on PrEP [25]. Sensitivity 
analyses of plausible combinations of these factors 
did not give a high degree of certainty that the ICER 
for PrEP would be below GBP 20,000 (EUR 27,210) 
per QALY gained [7]. Moreover, despite differences 
in model structure and input assumptions that were 
appropriate for England, these findings were broadly 
in agreement with economic evaluations from other 
23www.eurosurveillance.org
high income countries [26-29], which found ICERs to 
be highly dependent on HIV incidence, costs of the 
PrEP drug and adherence-related effectiveness. This 
analysis highlights critical considerations for PrEP 
implementation in other European countries, even if 
their HIV epidemic is different, as the problems arising 
around implementation, financial considerations, and 
programme sustainability are common.
A key strength of this study was the use of empirical 
data on many thousands of MSM attending GUM clinics 
in England over a contemporary period to measure HIV 
incidence and risk turnover. A critical assumption was 
that future HIV incidence in MSM GUM clinic attendees 
will replicate that observed between 2009 and 2013, 
and further consequences of any recent changes in 
sexual behaviour were not captured. However, it was 
reasonable to extrapolate forward current HIV inci-
dence estimates given the scale and timeliness of the 
source GUMCAD data and the recent back-calculation 
estimates that showed no change in overall HIV inci-
dence in MSM [1,30].
A major limitation of our analysis was the use of a 
static decision analysis approach instead of a dynamic 
transmission model, as it did not quantify the benefit 
of PrEP on the wider HIV epidemic in England, includ-
ing the benefits for those not given PrEP. Therefore, 
there was an underestimation of the total benefit. 
Nevertheless, since our cohort of 5,000 MSM was very 
small (1%) compared with the overall HIV-negative 
MSM population in England, and modest compared 
with the higher risk group of GUM attendees (29%), the 
likely indirect impact of the PrEP programme would be 
limited. Recently, Nichols et al. quantified this indirect 
effect of a similarly modest PrEP intervention (average 
4,500 MSM annually) delivered to a Dutch MSM popula-
tion using a dynamic model and showed only a 13–16% 
change in the ICER when indirect effects were included 
[26]. Therefore, with a modest programme, the majority 
of benefits fall on those given PrEP. Should a very large 
PrEP programme be implemented, the long-term indi-
rect effects would increase in dominance and a static 
modelling approach would be inappropriate.
In conclusion, whether or not PrEP drug is priced at a 
level that guarantees favourable cost effectiveness, 
reduced budgetary impact, and a shorter return on 
investment period, the analysis highlights other ques-
tions about PrEP scale-up that directly affect the finan-
cial considerations and the sustainability of any future 
programme. When proposed high-risk eligibility crite-
ria are implemented, who and how many will access 
and take up PrEP? Will PrEP be taken up by those in 
whom PrEP is clinically recommended? What will be 
their level of adherence? What will be the effectiveness 
of regular clinical risk assessment at assuring that only 
those at continuing high-risk stay on PrEP to maintain 
cost-effectiveness and equitable access based on clini-
cal need? These questions should be answered before 
embarking on a long-term PrEP-based intervention. A 
further clinical trial is proposed as a means to do this 
[31].
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